<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143081">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02108184</url>
  </required_header>
  <id_info>
    <org_study_id>PSungmin</org_study_id>
    <nct_id>NCT02108184</nct_id>
  </id_info>
  <brief_title>Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy</brief_title>
  <official_title>Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incheon St.Mary's Hospital</source>
  <oversight_info>
    <authority>Republic of Korea : KFDA</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the eradications rates of sequential therapy versus concomitant therapy of
      treatment of Helicobacter pylori infection in Korea.

      single center, randomized trial

        1. (pantoprazole 40 mg + amoxicillin 1.0g + clarithromycin 500 mg + metronidazole 500 mg)
           bid for 10 days

        2. (pantoprazole 40 mg + amoxicillin 1.0g + clarithromycin 500 mg + metronidazole 500 mg)
           bid for 14 days

        3. (pantoprazole 40 mg + amoxicillin 1.0g) bid for 5 days and subsequent  pantoprazole
           40mg + clarithromycin 500 mg + metronidazole 500 mg) bid for 5 days

        4. (pantoprazole 40 mg + amoxicillin 1.0g) bid for 7 days and subsequent  pantoprazole
           40mg + clarithromycin 500 mg + metronidazole 500 mg) bid for 7 days

      1st endpoint : Helicobacter pylori eradication rates (intention to treatment, per-protocol)
      2nd endpoint : adverse event(nausea, vomiting, dizziness, bitter sense) drug compliance
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea.</measure>
    <time_frame>required  average 10 weeks to assess Helicobacter pylori eradication rate from 1st visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess Helicobacter pylori eradication rates</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>pantoprazole, amoxicillin, clarithromycin, metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg )bid for the next 5 days : Sequential therapy 1
(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg )bid for 10 days : Concomitant therapy 1
(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole, amoxicillin, clarithromycin, metronidazole</intervention_name>
    <description>(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1</description>
    <arm_group_label>pantoprazole, amoxicillin, clarithromycin, metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole, amoxicillin, clarithromycin, metronidazole</intervention_name>
    <description>(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2</description>
    <arm_group_label>pantoprazole, amoxicillin, clarithromycin, metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole, amoxicillin, clarithromycin, metronidzole</intervention_name>
    <description>(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1</description>
    <arm_group_label>pantoprazole, amoxicillin, clarithromycin, metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole, amoxicillin, clarithromycin, metronidazole</intervention_name>
    <description>(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2</description>
    <arm_group_label>pantoprazole, amoxicillin, clarithromycin, metronidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20~70 patients

          -  agreement of informed consent

          -  H.pylori positive (biopsy, CLO)

          -  Peptic ulcer disease, mucosa associated lymphoid tissue lymphoma, Post endoscopic
             submucosal dissection status due to early gastric cancer

        Exclusion Criteria:

          -  H.pylori eradication history

          -  severe hepatic, renal, cardiac failure

          -  pregnancy, participant of other study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sung min Park</last_name>
    <phone>082-032-280-5052</phone>
    <email>danson2000@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Incheon St.Mary hospital</name>
      <address>
        <city>Incheon</city>
        <state>Bupyung</state>
        <zip>KSXX0009</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungmin Park</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter. 2013 Jun;18(3):180-6. doi: 10.1111/hel.12034. Epub 2013 Jan 11.</citation>
    <PMID>23305083</PMID>
  </reference>
  <results_reference>
    <citation>Kim JS, Kim BW, Ham JH, Park HW, Kim YK, Lee MY, Ji JS, Lee BI, Choi H. Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis. Gut Liver. 2013 Sep;7(5):546-51. doi: 10.5009/gnl.2013.7.5.546. Epub 2013 Aug 14.</citation>
    <PMID>24073312</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 10, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Incheon St.Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Sung min, Park</investigator_full_name>
    <investigator_title>fellow</investigator_title>
  </responsible_party>
  <keyword>helicobacter eradication rates</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
